13F Holdings
中文EN

RNA Atrium Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2093101 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets22.3%
Debt / equity0.00x
Current ratio10.46x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue$15.32M$3.00M$19.64M$12.34M$3.85M$1.57M
R&D expense$13.80M$15.34M$16.66M$9.75M$13.29M$6.94M
SG&A expense$8.15M$10.28M$20.26M$2.80M$3.42M$2.09M
Operating income-$6.63M-$22.62M-$17.28M-$213,000-$12.86M-$7.45M
Pretax income-$4.27M——-$213,000——
Income tax$0——-$176,000——
Net income-$4.27M-$20.19M-$16.63M-$37,000-$12.88M-$7.45M
EBITDA-$6.28M-$22.27M-$17.13M-$144,000-$12.79M-$7.40M
EPS (basic)-0.25-1.18-0.970.00-0.75-0.44
EPS (diluted)-0.25-1.18-0.970.00-0.75-0.44
Weighted avg. shares (diluted)17.04M17.11M17.11M17.11M17.11M17.11M
Balance sheet
Cash & equivalents$44.56M$72.33M$267.85M$0$0$0
Short-term investments$187.51M$191.57M————
Current assets$258.05M$275.05M$285.56M———
PP&E, net$4.19M$4.07M$4.34M———
Total assets$263.99M$280.51M$292.36M———
Current liabilities$24.66M$31.51M$21.91M———
Total liabilities$58.97M$65.94M$58.26M———
Shareholders' equity$205.02M$214.58M$234.10M-$57.15M-$56.18M-$56.30M
Shares outstanding16.40M17.11M17.11M———
Cash flow statement
Operating cash flow-$25.37M-$3.93M-$31.14M$1.13M-$11.91M-$11.10M
Capital expenditure$415,000$36,000$2.10M$300,000$266,000$0
Free cash flow-$25.78M-$3.96M-$33.24M$833,000-$12.17M-$11.10M
Investing cash flow$3.90M-$191.59M-$2.10M-$300,000-$266,000$0
Financing cash flow-$6.30M$0$301.50M-$833,000$12.17M$11.10M
Depreciation & amortization$352,000$343,000$151,000$69,000$79,000$53,000
Stock-based compensation$1.12M$893,000$12.21M$1.22M$1.70M$1.21M

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.